| 摘要: |
| 目的：观察舒肝化瘀方联合熊去氧胆酸胶囊（UDCA）治疗原发性胆汁性胆管炎（PBC）的临床疗效。方法：将50例PBC患者随机分为治疗组和对照组,每组各25例。对照组给予UDCA治疗,治疗组在对照组的基础上联合舒肝化瘀方治疗。2组疗程均为 48 周,观察2组治疗前后的主要症状、体征及肝功能指标、肝纤维化指标和不良反应发生情况。结果：治疗48周后治疗组中医证候总积分得到明显改善,2组中医证候疗效总有效率治疗组为92.00%（23/25）,对照组为84.00%（21/25）,组间比较,差异有统计学意义（P<0.01）。2组肝功能与肝纤维化各项指标均较治疗前明显改善（P<0.01）,且治疗组改善幅度优于对照组（P<0.01）。治疗期间2组均无明显不良反应。结论：舒肝化瘀方联合UDCA治疗PBC抗肝纤维化及改善肝功能疗效显著,安全性好,优于单用UDCA治疗。 |
| 关键词: 原发性胆汁性胆管炎 中西医结合疗法 舒肝化瘀方 熊去氧胆酸胶囊 |
| DOI： |
|
|
| Clinical effect of Shugan Huayu prescription combined with ursodeoxycholic acid capsules in treatment of primary biliary cholangitis：An analysis of 25 cases |
| XIE Xinke,XIE Wenpeng,WANG Man |
| (The Affiliated Hospital of Shaanxi University of Chinese Medicine,Xianyang 712046,Shaanxi,China;School of Medical Technology,Shaanxi University of Chinese Medicine,Xianyang 712046,Shaanxi,China) |
| Abstract: |
| Objective：To investigate the clinical effect of Shugan Huayu prescription combined with ursodeoxycholic acid (UDCA) capsules in the treatment of primary biliary cholangitis (PBC).Methods：A total of 50 patients with PBC were randomly divided into treatment group and control group,with 25 patients in each group.The patients in the control group were given UDCA,and those in the treatment group were given Shugan Huayu prescriptionin addition to the treatment in the control group.The course of treatment was 48 weeks for both groups,and the two groups were compared in terms of major symptoms and signs,liver function parameters,liver fibrosis indices,and adverse reactions before and after treatment.Results：After 48 weeks of treatment,the treatment group had a significant improvement in the total score of traditional Chinese medicine (TCM) syndrome,and there was a significant difference in the overall response rate of TCM syndrome between the treatment group and the control group ［92.00%(23/25)vs 84.00%(21/25),P<0.01］.Both groups had significant improvements in liver function parameters and liver fibrosis indices after treatment (P<0.01),and the treatment group had significantly greater improvements than the control group (P<0.01).No adverse reactions were observed in either group during treatment.Conclusion：Shugan Huayu prescription combined with UDCA can effectively improve liver fibrosis and liver function and has good safety in the treatment of PBC,with a better clinical effect than UDCA alone. |
| Key words: primary biliary cholangitis integrated traditional Chinese and Western medicine therapy Shugan Huayu prescription ursodeoxycholic acid capsules |
